초록 ▼

당뇨성 족부궤양을 포함하는 난치성 피부 질환 치료를 위한 새로운 약물 개발과 약물의 효율적인 전달을 위한 피부 외용제등 전달체재를 개발하는 것을 목표로 한다. 새로운 약물에 대한 신생혈관형성에 관련하여 in vitro와 in vivo 실험(wound healing test, hindlimb ischemia test, mesenteric artery test)에서 새로운 약물인 SKL2020이 신생혈관생성을 촉진시키는 것을 확인 했다. 새로운 약물의 전달체재로 경피 흡수가 가능한 연고제와 서방형 제재인 생분해성고분자(PLGA) mic

당뇨성 족부궤양을 포함하는 난치성 피부 질환 치료를 위한 새로운 약물 개발과 약물의 효율적인 전달을 위한 피부 외용제등 전달체재를 개발하는 것을 목표로 한다. 새로운 약물에 대한 신생혈관형성에 관련하여 in vitro와 in vivo 실험(wound healing test, hindlimb ischemia test, mesenteric artery test)에서 새로운 약물인 SKL2020이 신생혈관생성을 촉진시키는 것을 확인 했다. 새로운 약물의 전달체재로 경피 흡수가 가능한 연고제와 서방형 제재인 생분해성고분자(PLGA) micropatricle를 이용한 in vitro 실험 결과를 확인 했다. 두 전달체재를 이용하여 in vivo 실험(wound healing test, hindlimb ischemia test, mesenteric artery test)을 진행 중이다. 그 중 mesenteric artery 실험 결과에서는 생분해성고분자(PLGA) microparticle을 사용했을 때, 신생혈관생성이 대조군에 비해 더 활발히 일어나는 것을 확인할 수 있었다. 이 결과들을 바탕으로 실제 당뇨성 족부궤양 환자들이 사용할 수 있는 최적의 조건을 얻기 위해 계속 관련 연구들을 수행해 나갈 계획이다.

Abstract ▼

I. The purpose of study
We have a purpose to develop a new drug and efficient drug delivery system to treat lntractability skin diseases including Diabetic foot ulcers.
II. The content and scope of study
Diabetic foot ulcer is one of the major complications of Diabetes mellitus, It occurs

I. The purpose of study
We have a purpose to develop a new drug and efficient drug delivery system to treat lntractability skin diseases including Diabetic foot ulcers.
II. The content and scope of study
Diabetic foot ulcer is one of the major complications of Diabetes mellitus, It occurs in 15% of all patients with diabetes and precedes 84% of all lower leg amputations. Due to arterial abnormalities and diabetic neuropathy, as well as a tendency to delayed wound healing, infection or gangrene of the foot is relatively common. Ten to fifteen percent of diabetic patients develop foot ulcers at some point in their lives and foot related problems are responsible for up to 50% of diabetes related hospital admissions.
To treat diseases, that is a burn, wound healing, stroke and cardiac disorder etc.. as well as diabetic foot, needs new blood vessel inducement. Therefore, we verify a efficiency of drug to generate a new blood vessel formation using in vitro, ex vivo, in vivo test. We make a efficient drug delivery system to control drug release patterns. Then, we verify a efficiency of drug delivery systems to exoerimenton animals.
？III. The results of study
To investigate blood vessel growth, we carried out three in vitro tests, migration, proliferation and differentiation of endothelial cell, We got results that the new drug improve migration, proliferation and differentiation of endothelial cell, In ex vivo test, we investigated a aorta ring assay to verify new blood vessel growth of body tissues at outside the body. When we loaded a new drug from low concentration to high concentration, the formation of blood vessel growth was in proportion to the drug concentration. In in vivo test, we carried out the hindlimb ischemia of mouse model used osmotic pump to get prolonged drug release. It was found that blood vessel growth was imoroved by SKL-2020. At specific concentration, it has better effect than VEGF+FGF is a one of the best protein drugs to promote new vessels formation. To study direct injection of SKL-2020 drug, we carried out the hindlimb ischemia of mouse model. These data show that a new drug, SKL-2020, has a effiecacy in induction of blood vessel growth. To study other animal models, we carried out the in vivo test, Mouse corneal pocket model test. Notably, the number of microvessel induced by SKL-2020 was more than in controls. Also, We studied mesentery artery rat model assay, A new drug, SKL-2020, induced blood vessel growth, Aithough we have got good results that SKL-2020 imporve blood vessel growth in vitro, ex vivo, in vivo test, we needed to suggest an alternative because of frequent injection. It will give a problem that patients have difficulty to use. So, we developed SKL-2020 ointment type and PLGA microparticles including SKL-2020 to increase a drug efficiency. In two in vitro test, penetration test and release pattern test, we got good results. We are carrying out an experiment on animals(wound healing test) using SKL-2020 onitment. The PLGA microparticles were used in rat mesentery artery model assay. It was also found that blood vessel growth of rat injected a new drug was faster than it was in the control group. To study new vessel formation of SKL-2020, we have carried out in vitro, in vivo assays. Our study clearly shows that a new drug, SKL-2020, stimulated blood vessel growth. Our data suggest that SKL-2020 induce blood vessel growth. We will continue to carry out the study on SKL-2020 and further develop more efficient drug delivery system that are related to the current study.
IV. Further study of results
Our studys may provide an important therapeutic guideline that a new drug can induce blood vessel growth and efficient delivery system can control drug release. It is expected to apply efficient drug development for diabetic foot ulcers as well as other diseases.

목차 Contents

• 1. 겉표지 ...1
• 2. 제출문 ...3
• 3. 보고서 요약서 ...4
• 4. 요약문 (한글) ...5
• 5. 요약문 (영문) ...7
• 6. 연구 성과 실적 및 향후 계획 ...9
• 6.1. 총괄연구개발과제의 연구성과 실적 및 향후 계획...9
• 6.2 연구성과 유형별 세부 내역 ...10
• 7. 참여연구원 현황표 ...13
• I. 총괄연구과제 연구결과 ...15
• 1. 연구개발과제의 배경 및 필요성 ...17
• 2. 국내외 기술개발 현황 ...18
• 3. 연구개발과제의 추진체계 ...20
• 4. 연구개발수행 내용 및 결과 ...22
• 5. 목표달성도 및 관련분야 기여도 ...33
• 5.1. 총괄연구개발과제의 목표달성도 ...33
• 5.2. 관련분야 기여도 ...34
• 6. 향후 연구성과 추진 계획 ...35
• 7. 연구개발결과의 파급효과 ...35
• 7.1. 기술적 파급효과 ...35
• 7.2. 경제.산업적 파급효과 ...36
• 7.3. 사회적 파급효과 ...36
• 8. 연구개발결과의 활용계획 ...38
• 8.1. 연구개발결과의 활용계획 및 추가연구의 필요성 ...38
• 8.2. 사업화(기업화) 목표 달성도 및 계획 ...38
• 8.3. 사업화 수준(계획 및 완료 포함) ...38
• 9. 연구개발과정에서 수집한 해외과학기술정보 ...38
• 10. 참고문헌 ...38
• II. 첨부서류 ...39
• 1. 자체평가의견서 ...41
• 2. 실적 증빙자료 ...46